Jesse Richards

About this provider

Jesse Richards is listed in internal medicine in Tulsa, OK. Reported medical education includes Oklahoma State University College Of Osteopathic Medicine (2016). Languages listed: English.

Education & training

• OKLAHOMA STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE · 2016 Source ↗

Source-reported information; confirm current details directly.

Reported credentials

• Internal Medicine Source ↗
• Internal Medicine, Bariatric Medicine Source ↗
• Internal Medicine Source ↗

Source-reported information; confirm current details directly.

Reported affiliations

• BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA OU PHYSICIANS TULSA Source ↗

Source-reported information; confirm current details directly.

Selected publications

• Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study. · 2026 Source ↗
• Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria. · 2026 Source ↗
• Obesity medications and acquired hypothalamic obesity in adults: A two-case experience. · 2026 Source ↗
• Knowledge, Attitudes, and Practices in the Management of Childhood and Adolescent Obesity: A Survey of Primary Care Providers in the State of Oklahoma, USA. · 2026 Source ↗
• Congenital melanocytic nevi in Bardet-Biedl syndrome. · 2025 Source ↗
• Gastrointestinal-related side effects are key barriers to dietary fiber intake. · 2025 Source ↗
• Bariatric outcomes of high BMI patients with preoperative anti-obesity medications. · 2025 Source ↗
• Improving the diagnosis of hyperphagia in melanocortin-4 receptor pathway diseases. · 2025 Source ↗
• Correction to: Defining Hyperphagia for Improved Diagnosis and Management of MC4R Pathway-Associated Disease: a Roundtable Summary. · 2025 Source ↗
• Significantly higher rates of KIDINS220 polymorphisms in patients with obesity and end-stage renal disease. · 2025 Source ↗
• Defining Hyperphagia for Improved Diagnosis and Management of MC4R Pathway-Associated Disease: A Roundtable Summary. · 2025 Source ↗
• Response to the Letter to the Editor by Athinarayanan. · 2025 Source ↗
• Response to the Letter to the Editor by Bett et al. · 2024 Source ↗
• Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis. · 2024 Source ↗
• Nutritional considerations with antiobesity medications. · 2024 Source ↗
• Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. · 2024 Source ↗
• Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series. · 2023 Source ↗
• Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study. · 2023 Source ↗
• Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study. · 2023 Source ↗
• Case report of PLXNA4 variant associated with hyper-response to phentermine/topiramate pharmacotherapy: Potential genetic basis for superior weight loss response? · 2023 Source ↗
• Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs). · 2022 Source ↗

Source-reported information; confirm current details directly.